Meeting
2015 Genitourinary Cancers Symposium
Comparative effectiveness of first-line VEGF TKI followed by second-line therapy with either a VEGF TKI or an mTOR inhibitor in patients with metastatic renal cell carcinoma.
Authors
Shiven B. Patel
Huntsman Cancer Institute, University of Utah, Salt Lake City, UT
Shiven B. Patel , Srinivas Kiran Tantravahi , David Gill , Austin Poole , Joseph Merriman , Julia A. Batten , David D. Stenehjem , Neeraj Agarwal
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
General Poster Session C: Renal Cancer
Track
Renal Cell Cancer
Sub Track
Renal Cell Cancer
Citation
J Clin Oncol 33, 2015 (suppl 7; abstr 495)
DOI
10.1200/jco.2015.33.7_suppl.495
Abstract #
495
Poster Bd #
G23
Abstract Disclosures
Similar Posters
Poster
2015 Genitourinary Cancers Symposium
Everolimus (EVE) versus temsirolimus (TEM) after first-line treatment with VEGF TKI in patients with metastatic renal cell carcinoma.
First Author: Shiven B. Patel
Poster
2020 Genitourinary Cancers Symposium
Tivozanib as first-line treatment of metastatic renal cell carcinoma: A real-world outcome review in North-West of England, United Kingdom.
First Author: Sam Wong
Poster
2014 Genitourinary Cancers Symposium
Sequential treatment of advanced or metastatic renal cell carcinoma (mRCC): What is effective? Data from the German RCC registry.
First Author: Lothar Mueller
Poster
2014 Genitourinary Cancers Symposium
Duration of targeted therapy in metastatic renal cell carcinoma patients with ECOG PS>2.
First Author: Ilya Tsimafeyeu